187
Participants
Start Date
June 30, 2014
Primary Completion Date
April 30, 2015
Study Completion Date
April 30, 2015
Omaveloxolone Lotion 0.5%
Omaveloxolone lotion 0.5% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
Omaveloxolone Lotion 3%
Omaveloxolone lotion 3% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
Vehicle Lotion
Lotion vehicle manufactured to mimic RTA 408 lotion will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
3D conformal radiation therapy
45 50.4 Gy in 1.8 Gy per day, in addition to 10 - 16 Gy boost or 46 - 50 Gy in 2 Gy per day, in addition to 10 - 16 Gy boost, at the physician's discretion
Mount Nittany Medical Center, State College
Hughes Cancer Center, East Stroudsburg
Abington Memorial Hospital, Abington
CaroMont Health Comprehensive Cancer Center, Gastonia
Spartanburg Regional Medical Center - Gibbs Cancer Center, Spartanburg
21st Century Oncology - Carolina Regional Cancer Center, Myrtle Beach
AnMed Health Cancer Center, Anderson
John B. Amos Cancer Center, Columbus
Lakeland Regional Cancer Center, Lakeland
St. Vincent Anderson Regional Hospital Cancer Center, Anderson
Northern Indiana Cancer Research Consortium, South Bend
Parkview Research Center, Fort Wayne
Radiation Oncology Associates - Parkview Research Center, Fort Wayne
Columbia St. Mary's, Milwaukee
Mayo Clinic - LaCrosse, La Crosse
Sanford Research/USD, Sioux Falls
Sanford Health, Bismarck
University of Nebraska Medical Center - Eppley Cancer Center, Omaha
Willis-Knighton Cancer Center, Shreveport
St. John Health System, Tulsa
University of Texas Health Science Center at San Antonio, San Antonio
University of Colorado Hospital, Dept. of Radiation Oncology, Aurora
St. Joseph's Hospital and Medical Center, Phoenix
Ironwood Cancer and Research Centers, Mesa
Arizona Cancer Center, Scottsdale
Cancer Care Northwest, Spokane
Norwalk Hospital, Norwalk